Page last updated: 2024-12-08

6-methylthiopurine ribonucleoside-5'-phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-methylthiopurine ribonucleoside-5'-phosphate: causes cyotoxicity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID437075
MeSH IDM0042889

Synonyms (1)

Synonym
6-methylthiopurine ribonucleoside-5'-phosphate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" However, because of their complex metabolism and potential toxicities, optimal use of biomarkers to predict adverse effects and therapeutic response is paramount."( Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
Loftus, EV; Moon, W, 2016
)
0.43
"To provide a comprehensive review focused on pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in IBD."( Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
Loftus, EV; Moon, W, 2016
)
0.43
"Pre-treatment thiopurine S-methyltransferase typing plus measurement of 6-tioguanine nucleotides and 6-methylmercaptopurine ribonucleotides levels during treatment have emerged with key roles in facilitating safe and effective thiopurine therapy."( Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
Loftus, EV; Moon, W, 2016
)
0.43
"Measurement of thiopurine-related enzymes and metabolites reduces the risk of adverse effects and improves efficacy, and should be considered part of standard management."( Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
Loftus, EV; Moon, W, 2016
)
0.43
"Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adverse reactions of azathioprine and mercaptopurine in IBD patients, often related to high steady-state 6-methylmercaptopurine ribonucleotide (6-MMPR) metabolite concentrations."( Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
Coenen, MJ; de Jong, DJ; Derijks, LJ; Engels, LG; Franke, B; Guchelaar, HJ; Hooymans, PM; Klungel, OH; Scheffer, H; van Marrewijk, CJ; Verbeek, AL; Vermeulen, SH; Wong, DR, 2017
)
0.46
"To determine the predictive value of 6-MMPR concentrations 1 week after treatment initiation (T1) for the development of these adverse reactions, especially hepatotoxicity, during the first 20 weeks of treatment."( Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
Coenen, MJ; de Jong, DJ; Derijks, LJ; Engels, LG; Franke, B; Guchelaar, HJ; Hooymans, PM; Klungel, OH; Scheffer, H; van Marrewijk, CJ; Verbeek, AL; Vermeulen, SH; Wong, DR, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
"In this study in Crohn's disease patients no pharmacokinetic interaction was shown between adalimumab and the conventional thiopurines, azathioprine and mercaptopurine."( The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Bakker, JA; Bus, P; Engels, LG; Gilissen, LP; Hooymans, PM; Masclee, AA; Neef, C; Pierik, M; Seinen, ML; van Bodegraven, AA; Wong, DR, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.35)18.7374
1990's5 (21.74)18.2507
2000's2 (8.70)29.6817
2010's15 (65.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.07 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index5.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (21.74%)5.53%
Reviews1 (4.35%)6.00%
Case Studies1 (4.35%)4.05%
Observational0 (0.00%)0.25%
Other16 (69.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]